| Formulated as a pressurized metered-dose Aerosphere inhaler using co-suspension delivery technology. |
| Reduces exacerbation risk and improves lung function to a greater extent than budesonide/formoterol and/or glycopyrronium/formoterol. |
| Reduces the need for rescue medication and improves dyspnoea, HR-QOL and all-cause mortality rate. |
| Generally well tolerated. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.